Biomedicine and health industries
North China's Shanxi province is aiming to generate over 30 billion yuan ($4.24 billion) in the output value of is biomedicine and health industries by the end of 2020.
Of these sectors, the output value of the pharmaceutical industry will exceed 25 billion yuan, according to this year's provincial plan of biomedicine and health industrial development released by Shanxi Department of Industry and Information Technology on June 18.
Under the plan, the province will further exploit its local advantages and potentials for developing biomedicine and health industries.
It will optimize the layout planning of biomedical industrial clusters, clarify the leading industries and support industrial chains and enhance product supply capacity and quality.
A goal, for example, has been established for advancing the construction of 10 landmark projects within the current year with the project completion rate exceeding 60 percent.
Also there is a goal for promoting the development of 20 related companies with eight gaining annual sales over 1 billion yuan and boosting the cluster attractiveness of northern Shanxi's active pharmaceuticals ingredient and preparation industrial base, central Shanxi's Chinese patent medicine industrial base and southern Shanxi's newly-developed targeted special medicine industrial base.
Officials said that in addition, Shanxi will offer targeted and systematic health services and boost the growth of subdivisions of the health industry -- relying on integrating the mobile internet, cloud computing and big data with the biomedicine and health industries.